<DOC>
	<DOCNO>NCT01083680</DOCNO>
	<brief_summary>The purpose study intend evaluate long-term safety effectiveness adalimumab participant Crohn 's disease ( CD ) treat recommended product label .</brief_summary>
	<brief_title>Effectiveness Safety Patients With Crohn´s Disease Clinical Routine</brief_title>
	<detailed_description>This study 60-month prospective , multicenter , observational study adalimumab adult participant CD reside Germany . Visits schedule every 3 month first year every 6 month thereafter . Participants continue study maximum 60 month discontinuation adalimumab therapy .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Severe , active Crohn 's Disease patient insufficient response complete adequate therapy glucocorticoid and/or immunosuppressive drug and/or hypersensitivity therapy patient therapy contraindicate . Hypersensitivity drug one ingredient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Routine clinical setting</keyword>
	<keyword>Long-term efficacy safety</keyword>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Humira®</keyword>
	<keyword>Adalimumab</keyword>
</DOC>